

Sean D Sullivan Bscpharm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8642375/publications.pdf>

Version: 2024-02-01

109
papers

5,381
citations

126907

33
h-index

82547

72
g-index

109
all docs

109
docs citations

109
times ranked

6482
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes in high hypoglycaemia risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00306.	2.4	5
2	The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-40.	1.6	1
3	The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 41-41.	1.6	0
4	Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 570-570.	1.6	1
5	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-9.	0.9	0
6	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. <i>BMC Health Services Research</i> , 2022, 22, 432.	2.2	1
7	International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 566-572.	0.9	0
8	A pragmatic cluster-randomized trial of a standing physician order entry intervention for colony stimulating factor use among patients at intermediate risk for febrile neutropenia (SWOG S1415CD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1518.	1.6	1
9	A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for patients with cancer receiving myelosuppressive chemotherapy (SWOG S1415CD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1525-1525.	1.6	1
10	Overall survival (OS) of patients with TRK fusion-positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6579-6579.	1.6	0
11	Assessing the early impact of a hospital-based health technology assessment program, smart innovation. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, .	0.5	1
12	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. <i>Journal of Medical Economics</i> , 2021, 24, 563-569.	2.1	5
13	Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 223-239.	0.9	8
14	Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports. <i>Value in Health</i> , 2021, 24, 789-794.	0.3	6
15	Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1713-1721.	4.4	5
16	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020, 36, 571-581.	1.9	12
17	Application of Health Technology Assessment (HTA) to Evaluate New Laboratory Tests in a Health System: A Case Study of Bladder Cancer Testing. <i>Academic Pathology</i> , 2020, 7, 237428952096822.	1.1	2
18	A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2004-2012.	4.4	11

#	ARTICLE	IF	CITATIONS
19	Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 689-695.	0.9	6
20	Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Technology Assessment in Health Care, 2020, 36, 58-63.	0.5	8
21	The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 981-986.	0.9	9
22	Evolution of the AMCP Format for Formulary Submissions. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 696-700.	0.9	0
23	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Applied Health Economics and Health Policy, 2019, 17, 733-740.	2.1	7
24	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. Value in Health, 2019, 22, 661-668.	0.3	61
25	Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. Diabetes, Obesity and Metabolism, 2019, 21, 2123-2132.	4.4	24
26	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. BMC Medical Research Methodology, 2019, 19, 119.	3.1	26
27	The Economic Burden of Chronic Obstructive Pulmonary Disease in the Asia-Pacific Region: A Systematic Review. Value in Health Regional Issues, 2019, 18, 121-131.	1.2	10
28	Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models. Medical Decision Making, 2019, 39, 294-298.	2.4	17
29	133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk). Diabetes, 2019, 68, 133-LB.	0.6	3
30	Returns to scientific publications for pharmaceutical products in the United States. Health Economics (United Kingdom), 2018, 27, 282-293.	1.7	2
31	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. Obesity Surgery, 2018, 28, 1321-1328.	2.1	8
32	Pharmacists as health care providers: Lessons from California and Washington. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 39-44.	1.0	9
33	Clinical outcomes in real-world patients with type 2 diabetes switching from first-generation to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 2148-2158.	4.4	59
34	Price elasticities of pharmaceuticals in a value based formulary setting. Health Economics (United Kingdom), 2018, 27, 282-293.	1.7	2
35	Toward a Hedonic Value Framework in Health Care. Value in Health, 2017, 20, 261-265.	0.3	8
36	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. Journal of Comparative Effectiveness Research, 2017, 6, 461-470.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. International Journal of Breast Cancer, 2016, 2016, 1-10.	1.2	4
38	Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. American Journal of Public Health, 2015, 105, e64-e69.	2.7	50
39	A multifaceted hospitalist quality improvement intervention: Decreased frequency of common labs. Journal of Hospital Medicine, 2015, 10, 390-395.	1.4	75
40	Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast, 2015, 24, 3-11.	2.2	14
41	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.3	539
42	Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis. Value in Health, 2015, 18, 173-179.	0.3	28
43	Association of Early Imaging for Back Pain With Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2015, 313, 1143.	7.4	104
44	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. Journal of Oncology Practice, 2015, 11, e44-e49.	2.5	14
45	Role of Health Services Research in Producing High-Value Rehabilitation Care. Physical Therapy, 2015, 95, 1703-1711.	2.4	18
46	Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases. Applied Health Economics and Health Policy, 2014, 12, 547-557.	2.1	15
47	Level of asthma control and health care utilization in Asia-Pacific countries. Respiratory Medicine, 2014, 108, 271-277.	2.9	51
48	An Economic Framework For Preventive Care Advice. Health Affairs, 2014, 33, 2034-2040.	5.2	8
49	Asthma Control and Cost in Latin America. Value in Health Regional Issues, 2014, 5, 25-28.	1.2	9
50	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. Value in Health, 2014, 17, 525-536.	0.3	41
51	Comparative effectiveness research in the United States: a progress report. Journal of Medical Economics, 2013, 16, 295-297.	2.1	4
52	Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. Journal of Medical Economics, 2013, 16, 391-396.	2.1	26
53	Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. Journal of Comparative Effectiveness Research, 2012, 1, 241-255.	1.4	8
54	Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology, 2012, 129, S49-S64.	2.9	88

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. <i>Journal of Medical Economics</i> , 2011, 14, 609-616.	2.1	25
56	US health care reform: a work in progress. <i>European Journal of Health Economics</i> , 2010, 11, 117-118.	2.8	0
57	Evaluating HTA principles. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 429-430.	0.5	2
58	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 71-78.	0.5	52
59	A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2009, 29, 1280-1288.	2.6	13
60	Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovascular Diabetology</i> , 2009, 8, 12.	6.8	21
61	Health Technology Assessment in Health-Care Decisions in the United States. <i>Value in Health</i> , 2009, 12, S39-S44.	0.3	73
62	Key principles for the improved conduct of health technology assessments for resource allocation decisions. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 244-258.	0.5	356
63	A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach. <i>Medical Care</i> , 2008, 46, 542-548.	2.4	12
64	The Promise of Specialty Pharmaceuticals: Are They Worth the Price?. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 3-6.	2.2	17
65	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. <i>Journal of Asthma</i> , 2007, 44, 189-194.	1.7	15
66	Updated Evaluation of the Cost-effectiveness of Lung Volume Reduction Surgery. <i>Chest</i> , 2007, 131, 823-832.	0.8	49
67	Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1494-1499.	2.8	22
68	Quality of clinical and economic evidence in dossier formulary submissions. <i>American Journal of Managed Care</i> , 2007, 13, 401-7.	1.1	7
69	Economic Evaluation in the US. <i>Pharmacoeconomics</i> , 2006, 24, 1163-1168.	3.3	27
70	Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, 726-735.	2.2	40
71	Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery. <i>Value in Health</i> , 2006, 9, 68-76.	0.3	19
72	Managing Biotechnology In A Network-Model Health Plan: A U.S. Private Payer Perspective. <i>Health Affairs</i> , 2006, 25, 1347-1352.	5.2	9

#	ARTICLE	IF	CITATIONS
73	More Isnâ€™t Always Better: Cost-Effectiveness Analysis and the Case for Using a Split-Night Protocol. <i>Journal of Clinical Sleep Medicine</i> , 2006, 02, 155-154.	2.6	10
74	Practice-Level Effects of Interventions to Improve Asthma Care in Primary Care Settings: The Pediatric Asthma Care Patient Outcomes Research Team. <i>Health Services Research</i> , 2005, 40, 1737-1757.	2.0	37
75	Evidence, Economics, And Emphysema: Medicareâ€™s Long Journey With Lung Volume Reduction Surgery. <i>Health Affairs</i> , 2005, 24, 55-66.	5.2	33
76	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. <i>JAMA Pediatrics</i> , 2005, 159, 428.	3.0	62
77	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 277-283.	1.6	256
78	Development of a Quantifiable Symptom Assessment Tool for Patients with Chronic Bronchitis: The Chronic Bronchitis Symptoms Assessment Scale. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 209-216.	1.6	10
79	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 277-283.	1.6	8
80	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic-Asthma Care. <i>JAMA Pediatrics</i> , 2004, 158, 875.	3.0	137
81	Rapporto costo-efficacia della terapia peginterferone Î±-2a + ribavirina in confronto a interferone Î±-2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. <i>Pharmacoeconomics Italian Research Articles</i> , 2004, 6, 105-114.	0.2	6
82	Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naïve Chronic Hepatitis C. <i>Pharmacoeconomics</i> , 2004, 22, 257-265.	3.3	63
83	A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism. <i>Pharmacoeconomics</i> , 2004, 22, 605-620.	3.3	29
84	Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management. <i>American Journal of Managed Care</i> , 2004, 10, S242-4; discussion 245-51.	1.1	2
85	A Randomized Controlled Clinical Trial to Improve Asthma Care for Children Through Provider Education and Health Systems Change: A Description of the Pediatric Asthma Care Patient Outcome Research Team (PAC-PORT II) Study Design. <i>Health Services and Outcomes Research Methodology</i> , 2003, 4, 265-282.	1.8	12
86	Resource costs for asthma-related care among pediatric patients in managed care. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 91, 251-257.	1.0	46
87	Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 1229-1236.	2.9	69
88	Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery. <i>Pharmacoeconomics</i> , 2003, 21, 477-496.	3.3	58
89	Comparison of Directly Elicited Preferences to Preferences Derived from the SF-36 in Adults with Asthma. <i>Medical Decision Making</i> , 2003, 23, 323-334.	2.4	28
90	The Economics of Venous Thromboembolism Prophylaxis. <i>Chest</i> , 2003, 124, 393S-396S.	0.8	14

#	ARTICLE	IF	CITATIONS
91	Cost Effectiveness of Lung-Volume Reduction Surgery for Patients with Severe Emphysema. New England Journal of Medicine, 2003, 348, 2092-2102.	27.0	218
92	Emerging Therapeutic Strategies for Asthma Management. Journal of Managed Care Pharmacy, 2003, 9, 14-21.	2.2	4
93	Introduction. Journal of Managed Care Pharmacy, 2003, 9, 2-2.	2.2	3
94	Asthma in the United States: Recent Trends and Current Status. Journal of Managed Care Pharmacy, 2003, 9, 3-7.	2.2	28
95	The cost-effectiveness of an inner-city asthma intervention for children. Journal of Allergy and Clinical Immunology, 2002, 110, 576-581.	2.9	129
96	Health State Preference Assessment in Diabetic Peripheral Neuropathy. Pharmacoeconomics, 2002, 20, 1079-1089.	3.3	24
97	Health Economics. , 2002, , 657-671.		2
98	The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology, 2001, 107, 3-8.	2.9	490
99	AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. Journal of Managed Care Pharmacy, 2001, 7, 272-282.	2.2	65
100	Modeling the Cost and Outcomes of Pharmacist-Prescribed Emergency Contraception. American Journal of Public Health, 2001, 91, 1443-1445.	2.7	35
101	Design Issues for Conducting Cost-Effectiveness Analyses Alongside Clinical Trials. Annual Review of Public Health, 2001, 22, 129-141.	17.4	46
102	The Economic Burden of COPD. Chest, 2000, 117, 5S-9S.	0.8	507
103	Trends in the cost of illness for asthma in the United States, 1985-1994. Journal of Allergy and Clinical Immunology, 2000, 106, 493-499.	2.9	328
104	The economic burden of asthma in US children: Estimates from the National Medical Expenditure Survey. Journal of Allergy and Clinical Immunology, 1999, 104, 957-963.	2.9	182
105	Intention-to-Treat Analysis in Randomized Trials: Who Gets Counted?. Journal of Clinical Pharmacology, 1997, 37, 667-672.	2.0	24
106	National Asthma Education and Prevention Program Working Group Report on the Cost Effectiveness of Asthma Care. American Journal of Respiratory and Critical Care Medicine, 1996, 154, S84-S95.	5.6	136
107	A Utility Assessment of Oral and Intravenous Ganciclovir for the Maintenance Treatment of AIDS-Related Cytomegalovirus Retinitis. Pharmacoeconomics, 1996, 10, 623-629.	3.3	17
108	Home care reimbursement for intravenous ganciclovir therapy. American Journal of Health-System Pharmacy, 1996, 53, 161-163.	1.0	3

#	ARTICLE	IF	CITATIONS
109	The Economic Costs of Asthma. Pharmacoeconomics, 1993, 4, 14-30.	3.3	63